Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.

Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging. Histol Histopathol. 2020 Dec 11;:18288 Authors: Lam AK, Ishida H Abstract The nomenclature and classification of pancreatic neuroendocrine neoplasms has evolved in the last 15 years based on the advances in knowledge of the genomics, clinical behaviour and response to therapies. The current 2019 World Health Organization classification of pancreatic neuroendocrine neoplasms categorises them into three groups; pancreatic neuroendocrine tumours (PanNETs)(grade 1 grade 2, grade 3), pancreatic neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) based on the mitotic rate, Ki-67 index, morphological differentiation and/or co-existing tissue subtype. PanNETs are also classified into non-functional NET, insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, ACTH-producing NET and serotonin producing NET based on hormone production and clinical manifestations. A portion of the cases were associated with genetic syndromes such as multiple neuroendocrine neoplasia 1 (MEN 1), neurofibromatosis and Von Hippel-Lindau syndrome. In view of the distinctive pathology and clinical behaviour of PanNENs, the current 8th AJCC/UICC staging system has separated prognostic staging grouping for PanNETs from the pancreatic neuroendocrine carcinomas or MiNENs. Pancreatic neuroendocrine carcinomas and MiNENs are staged according to the prognostic sta...
Source: Histology and Histopathology - Category: Cytology Tags: Histol Histopathol Source Type: research

Related Links:

ConclusionThe 12-gene prognostic model may serve as a useful complementary clinical risk-stratification tool for stage I and especially stage IA lung squamous cell carcinoma patients to guide clinical decision making.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
ConclusionAPBI with SBRT and ExacTrac Adaptive Gating System was feasible. The acute and late toxicities were almost null and cosmesis was excellent. We also found that the margins of 5  mm applied from CTV to PTV were sufficient to compensate for geometric uncertainties.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsCirc_0091579 accelerated Warburg effect and tumor growth via upregulating H3F3B via adsorbing miR-624 in HCC, providing evidence to support the involvement of circ_0091579 in the progression of HCC.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Squamous Cell Carcinoma of Head and Neck Interventions:   Drug: Atezolizumab;   Radiation: Stereotactic Body Radiation Therapy Sponsors:   University of Colorado, Denver;   Genentech, Inc.;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hepatocellular Carcinoma and Liver Disease Intervention:   Diagnostic Test: Helio Liver Test Sponsor:   Laboratory for Advanced Medicine, Indiana Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hepatocellular Carcinoma Interventions:   Drug: Idarubicin Hydrochloride for Injection;   Drug: Epirubicin Sponsor:   Zhejiang Cancer Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Oligometastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Drug: Placebo Administration;   Other: Quality-of-Life Assessment;   Drug: Relugolix;   Radiation: Stereotactic Body Radiation Therapy Sponsors:   NRG Oncology;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pancreatic Cancer Interventions:   Drug: Cabozantinib;   Drug: Pembrolizumab Sponsors:   Joseph Kim;   Exelixis;   Merck Sharp & Dohme Corp. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pancreas Cancer Intervention:   Sponsors:   University of Oklahoma;   Natera, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pancreatic Cancer Intervention:   Drug: CEND-1 Sponsors:   Qilu Pharmaceutical Co., Ltd.;   Cend Therapeutics Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer & Oncology | Carcinoma | Cytology | Gastroenterology | Genetics | Hormones | International Medicine & Public Health | Neurofibromatosis | Neurology | Pancreas | Pancreatic Cancer | Pathology | VIPoma | WHO